Print 16 July 2015
SANTA CLARA, Calif., July 16, 2015 /PRNewswire-iReach/ -- Global aesthetic company Miramar® Labs, Inc., announced today that it has received State Food & Drug Administration (SFDA) approval for the marketing and sale of the miraDry® system in the People's Republic of China. The approval follows US Food and Drug Administration (FDA) clearance of miraDry in January 2011and (CE) Mark approval in December 2013. The miraDry system utilizes the Company's proprietary miraWave™ technology and is the first system to permanently eliminate apocrine and eccrine glands in the axilla which are the cause of unwanted sweat and odor.
"We are excited that miraDry has received marketing and sales approval for the Chinese market," commented Mike Kleine, CEO and President of Miramar Labs. "This approval represents a significant opportunity in furthering our expansion in the Asian markets and fortifies our global leadership in the aesthetic market for sweat and odor reduction."
The miraDry system is currently distributed in over forty  countries worldwide. The company reports over 40,000 miraDry treatments, and sweat reduction is one of the fastest growing segments in aesthetics. With a population of over 1.4 billion people, expansion into China represents the largest growth opportunity for miraDry, as well as the aesthetic market, and the company is targeting very robust system sales in the first year alone.
About Miramar Labs:
Founded in 2006, Miramar Labs is a privately-owned global medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company's first priority is the treatment of bothersome underarm sweat, an issue that millions of people deal with daily. Physicians and patients are encouraged to visit www.miramarlabs.com for additional information aboutMiramar Labs.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
20 September 2017
19 September 2017